Necroptosis pathway protein

Necroptosis pathway proteins are a group of intracellular mediators that collectively regulate necroptosis, a form of programmed necrotic cell death distinct from apoptosis. The canonical necroptosis signaling module comprises receptor-interacting serine/threonine-protein kinase 1 (RIPK1), receptor-interacting serine/threonine-protein kinase 3 (RIPK3), and mixed lineage kinase domain-like protein (MLKL) pseudokinase[1][6][10]. These proteins assemble into a multiprotein complex called the “necrosome” in response to inflammatory or infection signals—particularly following stimulation by death ligands (e.g., TNF or FasL) when caspase activity is inhibited[1][3][10]. In this pathway, RIPK1 and RIPK3 interact and phosphorylate each other, then RIPK3 phosphorylates MLKL, leading to MLKL oligomerization, translocation to the plasma membrane, and disruption of membrane integrity, culminating in cell death. Necroptosis has key roles in host defense, clearance of pathogens, and regulating inflammation, but aberrant or excessive activation contributes to pathology in a range of diseases, including neurodegeneration, cardiovascular injury, cancer, and infection[3][5][4]. Several inhibitors for these proteins have been developed and evaluated preclinically—with varying success—for their potential to prevent necroptosis-mediated tissue damage, notably necrostatin-1 (RIPK1 inhibitor) and GSK′872 (RIPK3 inhibitor), among others[2][6]. Note: “Necroptosis pathway proteins” is not a single molecule but an umbrella term for multiple discrete proteins that make up the pathway. For structured information, entities such as "Receptor-interacting serine/threonine-protein kinase 1" (RIPK1), "Receptor-interacting serine/threonine-protein kinase 3" (RIPK3), and "Mixed lineage kinase domain-like protein" (MLKL) should be considered individually.

Other names

Necroptosis mediatorsNecroptosis signaling proteinsCore necroptosis proteinsRHIM domain-containing proteins (context dependent)

Kinase inhibition (RIPK1, RIPK3), Inhibition of MLKL oligomerization/activity, Induced degradation (PROTAC/RIPK1), Disruption of necrosome complex formation, Blocking downstream signaling